Introduction
Oyaksungi-san (OY), also known as wuyaoshunqi-san in Chinese and uyakujyunki-san in Japanese, a traditional medicine for-other medical books, with minor differences in dosage of each constituent herbs. It has been widely prescribed in East Asia for hundreds of years for prevention and treatment of stroke, and consequent hemiplegia, paralysis, and ataxia. In addition, OY is known to have therapeutic effects on arthralgia, myalgia, and rheumatoid arthritis. Although scientific reports and evidence verifying efficacies of OY for these diseases cannot be found, research studies to determine any medicinal effects and activity mechanisms are actively being conducted. For example, recent studies have shown that OY has a protective effect against the H 2 O 2 -induced apoptosis of hippocampal cells 1 and anti-inflammatory effects on the peripheral blood cells of patients with cerebral infarction. 2 In addition, trigeminal neuralgia was significantly improved with a reduced dose of carbamazepine. 3 Other studies have shown an inhibitory effect on colon cancer cell proliferation by inducing autophagy 4 and inhibiting adipogenesis of adipocytes. 5 For each of the 12 component herbs in OY, Angelicae Dahuricae Radix has an analgesic effect, 6, 7 whereas Ephedrae Herba and Zingiberis Rhizoma are associated with pulmonary vascular responses 8 and peripheral circulation in autonomic disorders. 9 Batryticatus Bombyx and Cnidii Rhizoma are neuroprotective 10 and free radical scavenging agents. 11 Citri Unshii Pericarpium and Aurantii Fructus Immaturus accelerate gastrointestinal motility. 12, 13 Zingiberis Rhizoma Crudus mitigates brain damage related to cerebral ischemia 14 and shows anti-neuroinflammatory activity. 15 Linderae Radix protects against postischemic myocardial dysfunction. 16 Platycodi Radix and Citri Unshii Pericarpium show neuroprotective effects, including with regard to neuroblast cell proliferation. 17, 18 Many studies have attempted to identify and understand the medicinal functions, therapeutic activities, and chemical compounds in traditional materials with novel pharmaceutical effects, and herbs are now being actively examined by many laboratories and companies. This scientific and industrial endeavor may be due to the safety of traditional medicine, which has fewer side effects because it relies on folk remedies that use natural materials. Moreover, bioconversion (e.g., fermentation or biological transformation, typically using microbes) is becoming an important tool for the development of compounds with new functions and effects. The beneficial microbe Lactobacillus is typically used for these purposes, and related products and fermented materials have protective and therapeutic effects on toxicity, 19 inhibit cancer cell proliferation, 20 and increase the quantities of effective compound. 21 Compared to nonfermented OY, there is very little research on the efficacy increase or the improvement of medicinal properties by fermentation of OY. Moreover, medicinal and practical use in clinical application or bedside administration has not been carried out. Efficacy and activity improvement of fermented OY is still in the laboratorial research stage. Only one study on fermented OY has demonstrated the increased anti-inflammatory activity in mouse macrophage cells. 22 It is obvious that the achievement of safety in the absence of toxicity is the most important consideration when studying the activities and efficacy of potential pharmaceuticals to combat target diseases and ailments. For this reason, we conducted an acute single-dose toxicity and genotoxicity test, including bacterial reverse mutation, chromosomal aberration, bone marrow micronucleus, and chromatographic assays using fermented OY (OY744), prior to the efficacy and mechanism study. Overall, no toxicity was observed in OY744, which is suggestive of the safety and low toxicity of the fermented traditional medicine OY744 and may be a basis for research and development using bioconverted materials. As a whole, no toxicity was found in OY744 at all, and this result can be a predetermined evidence for safety and toxicity matters of fermented traditional medicine OY744, and preliminary informative reference in research and development using bioconverted materials.
Methods

Chemicals and reagents
For high-performance liquid chromatography (HPLC) analysis, acetonitrile was purchased from J. T. Bakers (Philipsburg, NJ, USA 
Preparation of OY and OY744
The 12 herbs and medicinal materials in OY were purchased from local vendor Hyundai Herb (Youngcheon, Korea) and authenticated by herb specialist. OY was prepared according to the prescription described in Korean traditional medical book Fang-Yao-He-Bian ( ), with slight modification (Table 1 ). Combined herb mixture was immersed in distilled water (DW) for 1 hour in an extractor (Cosmos-600, Kyungseo Machine, Incheon, Korea) at ambient temperature for high extraction yield and boiled for 3 hours at 115 • C. Solid insoluble residuals were filtered out using a standard test sieve (106 m, Retsch, Haan, Germany) and used for fermentation. OY extract was autoclaved and fermented by inoculating (1%, v/v) activated bacteria Bifidobacterium breve (1 × 10 6 -5 × 10 6 colony-forming units/mL in MRS broth, obtained from Korea Food Research Institute, Sungnam, Korea) and incubating for 48 hours with aeration at 37 • C. OY744 was then lyophilized in a freeze dryer (Ilshin, Dongducheon, Korea) and maintained at −20 • C until use. Part of OY744 was deposited in the institutional herbarium as a voucher specimen (Registration No. OY744).
Chromatographic analysis
To determine the phytochemical profiles and the contents of OY744, HPLC analysis was performed following a slightly mod- ified version of the method reported previously. 23 Briefly, the HPLC-diode-array detection system (Lachrom Elite, Hitachi High-Technologies Co., Tokyo, Japan) was used. Chromatographic separation was achieved with Phenomenex Luna C18 column (4. 
Experimental animals
Seven-week-old specific pathogen-free Sprague-Dawley rats and ICR mice were obtained from Orient Bio (Sungnam, Korea), and subjected to acute toxicity and micronucleus tests. Their exterior appearances were examined on acceptance, and they were housed and observed daily for general clinical signs during 1 week of quarantine and acclimation. Animals were then maintained under the following conditions: temperature: 22.7 ± 0.5 • C, humidity: 42.5 ± 1.5%, lighting: 12-hour (08:00-20:00, 290 lux), and ventilation (10-15 times/hour). Diet pellets (Harlan Laboratories, IN, USA) and filtered tap water were supplied ad libitum. This study using laboratory animals was approved by the Institutional Animal Care and Use Committee of Kore Institute of Oriental Medicine.
Acute toxicity
After 1 week of acclimation and quarantine, animals were divided into four experimental groups (5 males and 5 females in each group) according to body weight. Animals were fasted overnight and administered OY744 (dose volume of 10 mL/kg body weight dissolved in DW; 500 mg/kg, 1000 mg/kg, and 2000 mg/kg) using oral gavage. Diets and water were supplied again after 3 hours of administration. General behaviors, clinical signs, and mortality rates were observed once per day for 14 days, including once per hour during the 6 hours following administration. Body weights were recorded before and after administration on Days 1, 3, 7, and 14. Animals were euthanized by CO 2 asphyxia, and their organs were thoroughly examined for any gross alterations. Comparisons between each pair of group were made using one-way analysis of variance (ANOVA), and SPSS 12.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Acute toxicity assay was conducted according to the Korea Food and Drug Administration Notice #2009-183 (Good Laboratory Practice), and Notice #2009-116 (Guidelines for Toxicity Test of Drugs).
Bacterial reverse mutation assay
Bacterial reverse mutation assays were conducted using histidine auxotrophic Salmonella typhimurium (TA98, TA100, TA1535, and TA1537) and tryptophan auxotrophic Escherichia coli (WP2uvrA) purchased from Molecular Toxicology Inc. (Boone, NC, USA). Oxoid Nutrient Broth No. 2 (Thermo Scientific, Waltham, MA, USA) was used for preliminary cultivation in a shaking incubator for 10 hours at 180 rpm. Top agar for auxotrophic bacteria was composed of 5 g NaCl, 6 g Bactor agar, and 100 mL of 0.5 mM histidine/biotin in 1 L of DW. For tryptophan auxotrophic bacteria, 5 g NaCl, 6 g Bactor agar, and 100 mL of 0.5 mM tryptophan was used. Minimum glucose agar plates were prepared with 15 g agar, 20 g D-(+)-glucose minimum, and 100 mL of Vogel-Bonner medium E (10×). Vogel-Bonner medium E (10×) was prepared by dissolving 2 g MgSO 4 ·7H 2 O, 20 g citric acid·H 2 O, 100 g K 2 HPO 4 , and 35.8 g NaNH 5 PO 4 ·4H 2 O in 1 L DW. Preliminary incubation was conducted according to the method reported previously. 24 According to our preliminary study, OY744 was diluted in DW (313 g/plate, 625 g/plate, 1250 g/plate, 2500 g/plate, and 5000 g/plate) in triplicate for the assays with and without S9 mix metabolic activation. The S9 mix was composed of 10% S9 tissue fraction, 8 mM MgCl 2 , 33 mM KCl, 4 mM NADP, 4 mM NAD, and 5 mM glucose-6-phosphate in 100 mM phosphatebuffered saline (PBS, pH 7.4). Vehicle control was DMSO. The following positive controls (reference materials) were used in a metabolic non-activation system: AF-2 for TA98, TA100, and WP2uvrA; NaN 3 for TA1535; and 9-AA for TA1537. In the metabolic activation system, 2-AA was used as the positive control for all bacterial strains. A total of 0.1 mL of bacterial culture, 0.05 mL of test material OY744, 2.0 mL of top agar, and S9 mix (or 0.1 M PBS, pH 7.4, for the metabolic nonactivation system) were prepared on glucose agar plates and incubated at 37 • C for 48 hours. OY744 and S9 mix, without bacterial culture, were also plated together to ensure sterility. Abnormalities and contaminations were thoroughly observed, and revertants were counted using a colony counter. 25, 26 Briefly, cells were maintained in a 5% CO 2 incubator at 37 • C in F-12 nutrient mixture (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT, USA). Preliminary cytotoxicity was examined to observe any cytotoxic effect and to determine the concentration of OY744 (39.06 g/mL, 78.13 g/mL, 156.25 g/mL, 312.5 g/mL, 625 g/mL, 1250 g/mL, 2500 g/mL, and 5000 g/mL). Relative cell counts (RCCs) were determined by comparing cell counts in the treatment with those of the vehicle control as follows: RCC = (No. of treated cells/No. of control cells) × 100 (%). Cells (2 × 10 4 -4 × 10 4 ) were seeded in a 60-mm culture dish and incubated for 72 hours. After the medium was removed, 4.85 mL of a prewarmed fresh medium and 0.15 mL of OY744 (and 0.5 mL of S9 mix in a metabolic activation system) were added to a final volume of 5 mL and incubated for a further 6 hours (and 24 hours in the metabolic nonactivation system). The medium was removed again, and the cells were washed once with PBS and incubated for 18 hours with 5 mL of fresh prewarmed medium until metaphase cell harvest. 
Bone marrow micronucleus assay
Carcinogenicity was evaluated using the micronucleus test with male ICR mice under the same condition used for the animal laboratory environment (see descriptions as described in the section on experimental animals). A preliminary study was conducted to determine the dose range and bone marrow cell collecting time of five groups (three mice/group): the vehicle control, positive control (mitomycin C 2.0 mg/kg), and the three treatment groups (1250 mg/kg, 2500 mg/kg, and 5000 mg/kg). After 3 hours of fasting, vehicle control and OY744 were administered orally using sonde, and the positive control was injected intraperitoneally. Two sets of these five groups were prepared for 24 hours and 48 hours treatment. Because the preliminary tests revealed no effects on mortality, clinical signs, and bone marrow cell proliferation, the dose range for the main study was determined as it was in the preliminary tests. In the main study, all conditions and groups were the same as those in the preliminary study, but six mice were included in each group. After 24 hours of administration, bone marrow cells were collected via FBS washing from the excised femurs of mice sacrificed by cervical dislocation. Three slides were prepared from each animal by smearing, drying, and fixation (methanol, 5 minutes). Cells were then stained with Giemsa (4%) for polychromatic erythrocytes (PCEs) and with acridine orange (40 g/mL) for micronuclei in PCE. PCE with or without micronuclei and normochromatic erythrocytes (NCEs) were examined under light and fluorescent microscopes with the FITC filter. Cytotoxicity was evaluated by observing the PCE/NCE ratio in 200 erythrocytes. The frequency of micronucleated (MN) PCEs was observed in 2000 PCEs per animal. The micronuclei frequency and PCE/(PCE + NCE) ratio were statistically evaluated by one-way ANOVA. The results were considered reasonable when the PCE/(PCE + NCE) ratio was > 0.1, and they were considered positive when the micronuclei-inducing ratio (MNPCE/2000 PCEs) was statistically significant and it dose-dependently increased or when it was positive at one or more doses. It was considered statistically significant when p < 0. 
Results
Representative compounds were identified by chromatographic analysis
As shown in Fig. 1 , seven phytochemicals in OY744 were identified through retention time and the UV spectrum in the HPLC-diode-array detection system. The quantities of liquiritin, ferulic acid, naringin, hesperidin, neohesperidin, liquiritigenin, and glycyrrhizin were 0.14 mg/g, 1.21 mg/g, Fig. 1 -Three-dimensional high-performance liquid chromatogram of (A) standard compounds and (B) fermented oyaksungi-san (OY744).
7.22 mg/g, 2.20 mg/g, 3.88 mg/g, 0.18 mg/g, and 1.00 mg/g, respectively. Compound imperatorin was not detected in OY744.
3.2.
No toxicity and no abnormal findings were observed in acute toxicity assay using rats Single-dose acute toxicity was evaluated in the Sprague-Dawley rats in the three experimental groups (500 mg/kg, 1000 mg/kg, and 2000 mg/kg) and the control group. During the 14 days of the total experimental period, no mortality or no abnormal clinical signs were observed. Behaviors and external appearances were normal, and no gross lesions of internal organs were observed. The body weights of both male and female rats showed normal increases without any significant changes (Fig. 2) . According to these results, the lethal dose 50 (LD 50 ) of OY744 might be over 2000 mg/kg.
Antibacterial effects were not found with no increase of revertant colony numbers
In the dose-determining preliminary study, no antibacterial or growth inhibitory effects were observed up to concentrations of 5000 g/plate, regardless of metabolic activation. In the main study, no increases in the number of revertant colonies were observed in any bacterial strain at any concentration (Fig. 3). 
Chromosomal observations showed normal numerical and structural metaphases
In the preliminary metabolic nonactivation study, the cell viabilities of the 24 hours treatment group were 53.45% and 72.41% at 1250 g/mL and 625 g/mL, respectively; in the 6 hours treatment/18 hours recovery group, they were 57.06% and 61.58% at 5000 g/mL and 2500 g/mL, respectively. Accordingly, the maximum concentrations of the 24 hours and 6 hours treatment/18 hours recovery groups were 1250 g/mL and 5000 g/mL, respectively. In the metabolic activation system, the 6 hours treatment group showed 58.65% and 67.67% cell viability at 5000 g/mL and 2500 g/mL concentrations, respectively; we used 5000 g/mL as the maximum concentration for the main study. In the main study (metabolic nonactivation) for chromosomal aberration, the cell numbers of aberrant metaphase (gap-) were 0.0, 0.0, 0.0, and 0.5 in the negative control and 312.5 g/mL, 625 g/mL, and 1250 g/mL in the 24 hours treatment group. In the 6 hours treatment/18 hours recovery group, the comparable figures were 0.5, 0.5, 1.0, and 1.5, respectively; in the negative control group, they were 1250 g/mL, 2500 g/mL, and 5000 g/mL, respectively. Aberrant metaphase cell numbers in the metabolic activation system were 0.5, 0.0, 0.5, and 0.5 in the negative control group at 1250 g/mL, 2500 g/mL, and 5000 g/mL, respectively. As we observed no statistically significant increases with regard to polyploidy and endoreduplication (Table 2) , we concluded that OY744 had no effect on inducing chromosomal aberrations in CHO-K1 cells.
Micronucleus assay showed normal ranges in cytotoxic indicators
In the preliminary study, the MNPCEs per 2000 PCEs in the vehicle; the 1250 mg/kg, 2500 mg/kg, and 5000 mg/kg and the positive control MMC groups were 0.25, 0.23, 0.10, 0.15, and 11.52 and 0.23, 0.35, 0.22, 0.18, and 9.50 at sampling times of 24 hours and 48 hours, respectively (Fig. 4A) . Induced MNPCE ratios of 2000 PCEs per animal in the vehicle; 1250 mg/kg, 2500 mg/kg, 5000 mg/kg; and the positive control groups were 0.30%, 0.23%, 0.27%, 0.24%, and 10.11%, respectively, in the main study (Fig. 4B) . This reflected no statistically significant difference between vehicle and treatment groups. Instead, the positive control MMC group significantly differed from the vehicle group (p < 0.01). The cytotoxic indicators PCE/(PCE + NCE) in the preliminary study were 0.52, 0.43, 0.46, 0.42, and 0.43 at 24 hours sampling time and 0.43, 0.52, 0.46, 0.47, and 0.18 at 48 hours sampling time in the same control and treatment groups, respectively (Fig. 4C) . The PCE/(PCE + NCE) results in the main study were 0.47, 0.47, 0.54, 0.51, and 0.35, respectively, which reflected no significant inhibition of bone marrow cell proliferation (Fig. 4D ). There were no significant body weight changes in animals.
Discussion
For hundreds of years, numerous herbs and medicinal materials have been used for the treatment of many diseases and ailments. These compounds, especially those used in folk medicine, are considered to be safe medicinal materials with few side effects. Nowadays, traditional medicine has increased in popularity and attracted attention worldwide as its significant therapeutic activities and efficacy as a dietary supplement have been shown with regard to improving health and overall condition. 28 Traditional medicine is becoming more popular, and the sales of Chinese medicine accounted for US$83.1 billion in 2012, which represents an increase of >20% over the previous year. Expenditures for natural products in the US accounted for US$ 14.8 billion in 2008. 29 Thus, many indepth studies are being conducted to develop complementary and alternative pharmaceuticals. 30 Herbal medicines are typically believed to be less toxic than synthetic chemical drugs.
However, toxicity and safety assay are important for all pharmaceuticals. For this reason, we evaluated potential toxicities based on the single-dose acute toxicity and genotoxicities of OY744 using bacterial reverse mutation, chromosomal aberration, and micronuclei assays. The single-dose acute toxicity of OY744 (up to 2000 mg/kg) was observed during 14 days of animal experiments. No toxic clinical signs or parameters and no abnormal behaviors or local lesions of internal organs were observed throughout the experiments. Body weights also showed only normal increases; therefore, the LD 50 of OY744 may be over 2000 mg/kg. In the bacterial reverse mutation assay, mutations, such as frame-shift or base pair substitution and the number of revertant colonies were not affected at concentrations up to 5000 mg/kg. Based on this result, OY744 can be considered safe with no mutagenicity in the bacterial strains at any concentration. Observation of chromosomal aberrations involving structural and numerical abnormalities is one of the integral components of genotoxic assays. The mammalian cell line CHO-K1 is commonly used for the evaluation of potential clastogens, as they are well-known mutagensensitive and informative cells. Chromosomal aberrations such as gap, break, exchange, aneuploidy, and polyploidy were examined thoroughly in metaphase, and no mutagenic aberrations were observed at any concentration of OY744 with or without S9 mix. This result suggests that OY744 is not a clastogen in this assay system. The mutagenic toxicity of OY744 was also evaluated with bone marrow cells from ICR mice administered single doses of 1250 mg/kg, 2500 mg/kg, and 5000 mg/kg in both the preliminary (with sampling times of 24 hours and 48 hours) and main studies. In the preliminary study, no specific or significant differences in the appearance of the treatment and vehicle control groups were observed. Based on the results of the preliminary study, the main study was conducted with the highest concentration, 5000 mg/kg, and a sampling time of 24 hours, which produced no significant inhibition of bone marrow cell proliferation (i.e., ratio of PCE/NCE). No significant differences were observed regarding MNPCEs compared with the vehicle control, whereas the positive control showed a significant increase in this regard. Based on these results, OY744 is not inducible for micronuclei in bone marrow cells under these experimental conditions.
There are several studies on the pharmaceutical efficacy and biological activities of OY, as described in the Introduction. Based on further studies, concerns about safety issues have increased as new materials and new uses for extant materials have been developed. However, despite the need for research on safety, studies regarding toxicity have not been reported. Furthermore, traditional medicines are typically composed of natural materials and herbs and are processed either physically or biologically. Traditional medicine and herbs are heat or naturally dried, boiled, and steamed in the preparation of the formula, prescription, and decoction. Moreover, in biological processes, microbes are used for the fermentation of the herb extract and to prepare probiotics. The achievement of safety in the absence of toxicity is fundamental in the development of pharmaceuticals and in research using herbs. The present research involved a single-dose acute and genotoxicity study on the fermented traditional medicine OY744. Fermented OY has not been used in clinical practice and also not been prescribed as a medicine in healthcare system. It is still under research in this laboratory for later development of pharmaceuticals and medical applications. There are many research reports and comments on beneficially improved and strengthened efficacies, 31, 32 and biological and medical usefulness is recognized elsewhere, with increasing scientific evidence regarding targeted therapeutic activities in many diverse diseases and ailments. However, these research reports should be the solid basis for development of medicines with further studies and clinical trials. The importance of toxicity testing prior to the development of medicines is undoubtedly important Taken together, none of the observations or findings revealed toxicity or mutagenicity. This result can be used as basis for the development of traditional pharmaceuticals and the performance of related researches of complementary and alternative medicines.
